Lance Armstrong's Livestrong Summit: City hosting 1,000 soldiers in war on cancer THE COLUMBUS DISPATCH J.Scott Applewhite | Associated Press Lance Armstrong will be in the city for his cancer foundation's summit today through Sunday.
More coverage So much has yet to be won in the war on cancer declared...
City hosting 1,000 soldiers in war on cancer Lance Armstrong's Livestrong Summit THE COLUMBUS DISPATCH So much has yet to be won in the war on cancer declared 37 years ago by President Nixon.Precious and abundant are those things that remain to be gained: high quality of life...
City hosting 1,000 soldiers in war on cancer Lance Armstrong's Livestrong Summit THE COLUMBUS DISPATCH So much has yet to be won in the war on cancer declared 37 years ago by President Nixon.Precious and abundant are those things that remain to be gained: high quality of life...
A Primer on Blood Pressure ' High, Low, Dysregulated 'The brain provides nerves connecting to muscles in the blood vessel walls, telling them either to contract or relax.If this automatic control is damaged then postural hypotension is one result.' Sarah Myhill, MD Dr.
Sarah Myhill, MD,...
Grave's Ophthalmopathy After Radiation Treatment of Thyroid Cancer _ Grave's Ophthalmopathy After Radiation Treatment of Thyroid Cancer.
Dr. Fortanasce Explains the Alzheimer's Disease Crisis and a Protocol to Prevent or Delay It - at Any Age To make people believe that we are on the verge of a cure is like believing we can protect our children from lifes hardships.We cannot...
Alzheimers disease is lifestyle induced and begins in childhood...
It will attack us.
We can...
Living near chemical plants effects diabetes Allen Silverstone, Ph.D., an immunotoxicologist at SUNY Upstate Medical University in Syracuse, N.Y., explains how the residents of Anniston, Ala., are battling a secret killer that has been lurking in their soil for years.Q: What is a...
Exelixis begins phase 3 trial of thyroid cancer drug XL184 Exelixis, Inc.announced that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated.
XL184 is a small molecule anticancer compound targeting the MET, RET, and...
Erbitux boosts Merck KGaA sales as net income doubles Germanys Merck KGaA says that second-quarter net income more than doubled to 211.2 million euros, boosted by strong sales of the cancer drug Erbitux.Operating profit was up 15.5% to 320.5 million euros and group turnover climbed 6.1...
Genzyme Corp. Q2 2008 Earnings Call Transcript Thanks, Mary Ann, and welcome everyone to Genzyme Corporation's second quarter Earnings Call.On this call, we will be making forward-looking statements, including providing EPS guidance, discussing our product development plans and...
Glaxo Deal Opens Way for Aspen to Grow (Business Day/All Africa Global Media via COMTEX News Network) -- Africa's biggest generic drug maker, Aspen Pharmacare, has clinched a licensing and distribution deal with pharmaceutical giant GlaxoSmithKline that will see its products...
Diabetes Experts Recommend One-Two Punch for Treating Patients with Pre-Diabetes - For the first time, a consensus of diabetes and metabolic disorder experts have recommended a comprehensive treatment regimen for patients with pre-diabetes.The recommendations call for specific guidelines on both lifestyle, and...
ZIOPHARM Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at AACR Centennia - ZIOPHARM Oncology, Inc.(NASDAQ:ZIOP) announced today that it presented data from two Phase I studies of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the American Association for Cancer ...
ZIOPHARM Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at AACR Centennia Studies Demonstrate Indibulin is Well Tolerated and Shows Early Activity in Several Tumor Types MONTEREY, Calif.--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc.(NASDAQ:ZIOP - News) announced today that it presented data from two Phase I studies...
TopAbstracts in Thyroid Disorders 07/22/2008 TopAbstracts in Thyroid Disorders are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer...
ZIOPHARM Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at AACR Centennia , 7:30 AM EST News source: Business Wire ZIOPHARM Oncology, Inc.(NASDAQ:ZIOP) announced today that it presented data from two Phase I studies of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the...
ZIOPHARM Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at AACR Centennia - ZIOPHARM Oncology, Inc.(NASDAQ:ZIOP) announced today that it presented data from two Phase I studies of indibulin, the Company's novel, orally administered, synthetic tubulin targeted agent, at the American Association for Cancer ...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
Genzyme Reports Strong Second-Quarter Growth CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Genzyme Corporation (Nasdaq: GENZ) today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs.Revenue...
